Trial
NCT00288522
Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Ipsen
Collaborators
—
Condition
Thyroid-Associated Ophthalmopathy
Intervention
Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-06-02